Section Arrow
Quote
NAMS.NASDAQ
- NewAmsterdam Pharma Company NV
Quotes are at least 15-min delayed:2026/03/05 17:41 EST
After Hours
Last
 30.14
+0.02 (+0.07%)
Bid
29.7
Ask
30.4
High 30.14 
Low 30.14 
Volume 16.78K 
Regular Hours (Closed)
Last
 30.12
-1.06 (-3.40%)
Day High 
30.63 
Prev. Close
31.18 
1-M High
37.76 
Volume 
1.34M 
Bid
29.7
Ask
30.4
Day Low
29.65 
Open
30.63 
1-M Low
30.122 
Market Cap 
3.58B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 34.16 
20-SMA 34.28 
50-SMA 33.91 
52-W High 42 
52-W Low 14.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.72/0.47
Enterprise Value
3.58B
Balance Sheet
Book Value Per Share
5.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.50M
Operating Revenue Per Share
0.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1048+0.0008+0.77%-- 
After Hours 0.1024 -0.0024 -2.29%
IBOImpact BioMedical Inc.0.6425+0.2292+55.46%-- 
After Hours 0.5703 -0.0722 -11.24%
TNYATenaya Therapeutics0.81955+0.23065+39.17%-- 
After Hours 0.7959 -0.02365 -2.89%
IOVAIovance Biotherapeutics4.595+0.355+8.37%-- 
After Hours 4.5967 +0.0017 +0.04%
GOSSGossamer Bio0.5218-0.0579-9.99%-- 
After Hours 0.514 -0.0078 -1.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.